Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific basis for treating Alzheimer’s disease as a multi-protein disorder, emphasizing the company’s approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap.
Buntanetap is currently in a pivotal Phase 3 clinical trial. The investigational once-daily oral therapy inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This presentation is significant because it highlights a shift in Alzheimer’s research from targeting single proteins to a multi-protein strategy. Traditional approaches have focused on clearing amyloid beta plaques, but clinical outcomes have been mixed. Annovis’ approach targets several proteins implicated in neurodegeneration, potentially offering a more comprehensive treatment. If successful, buntanetap could address both Alzheimer’s and Parkinson’s diseases, which share overlapping pathological features.
For investors, the presentation at Fierce Biotech Week provides an opportunity to hear directly from the CEO about the scientific rationale and trial progress. The company’s stock may be influenced by updates on the Phase 3 trial, which is a key milestone. The broader biotechnology sector will be watching for data that could validate the multi-protein approach, potentially opening new avenues for drug development.
Annovis Bio is headquartered in Malvern, Pennsylvania. For more information, visit the company’s website at www.annovisbio.com and follow on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
